Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Andrés Poveda(Hospital Quirónsalud Barcelona), Éric Pujade-Lauraine(Eau de Paris (France)), Michael Friedländer(Prince of Wales Hospital), Tomasz Huzarski(International Hereditary Cancer Center), Alessandra Baldoni(Mario Negri Institute for Pharmacological Research), Elias Abdo Filho(Universidade de São Paulo), Jacob Korach(Tel Aviv University), Gabe S. Sonke(Oncode Institute), Ignace Vergote(KU Leuven), Alla Lisyanskaya(City Clinical Oncology Center), Philip Rowe(University of Strathclyde), Tjoung‐Won Park‐Simon(Medizinische Hochschule Hannover), Jonathan A. Ledermann(London Cancer), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Richard T. Penson(Massachusetts General Hospital), Anne Floquet(Institut Bergonié), Jae‐Hoon Kim(Bio-Medical Science (South Korea)), Amit M. Oza(Ontario Institute for Cancer Research), Rebecca Asher(The University of Sydney)
Cited by 110
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k